Pulte Dianne, Jansen Lina, Brenner Hermann
Division of Clinical Epidemiology and Aging Research
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Oncologist. 2017 Mar;22(3):351-358. doi: 10.1634/theoncologist.2016-0274. Epub 2017 Feb 20.
Rectal cancer (RC) is a common malignancy with a substantial mortality but good survival for patients with optimally treated nonmetastatic disease. Lack of insurance may compromise access to care and therefore compromise survival. Here, we examine RC survival by insurance type.
Data from the Surveillance, Epidemiology, and End Results database were used to determine 1- to 3-year survival for patients with RC by insurance type (Medicaid, uninsured, other insurance).
Patients with Medicaid or no insurance presented at later stages and were less likely to receive definitive surgery. Overall 3-year survival was higher for patients with other insurance compared with Medicaid-insured (+22.2% units) and uninsured (+18.8% units) patients. Major differences in survival were still observed after adjustment for stage. When patients with stage II and III RC were considered, 3-year survival was higher for patients with other insurance versus those with Medicaid (+16.2% units) and uninsured patients (+12.2% units). However, when the analysis was limited to patients with stage II and III disease who received radiation therapy followed by definitive surgery, the difference decreased to +11.8% units and +7.3% units, respectively, for Medicaid and no insurance.
For patients with stage II and III RC, much of the difference in survival between uninsured patients and those with insurance other than Medicaid can be explained by differences in treatment. Further efforts to determine the cause of residual differences as well as efforts to improve access to standard-of-care treatment for uninsured patients may improve population-level survival for RC. 2017;22:351-358 IMPLICATIONS FOR PRACTICE: Insurance status affects survival for patients with rectal cancer, but a substantial proportion of the difference in survival can be corrected if standard-of-care treatment is given. Every effort should be made to ensure that uninsured or publically insured patients receive standard-of-care treatment with as little delay as possible to improve patient outcomes.
直肠癌(RC)是一种常见的恶性肿瘤,死亡率较高,但对于接受最佳治疗的非转移性疾病患者而言,生存率良好。缺乏保险可能会影响医疗服务的可及性,进而影响生存率。在此,我们按保险类型研究直肠癌的生存率。
利用监测、流行病学和最终结果数据库的数据,按保险类型(医疗补助、未参保、其他保险)确定直肠癌患者1至3年的生存率。
参加医疗补助或未参保的患者就诊时分期较晚,接受根治性手术的可能性较小。与参加医疗补助保险的患者(高22.2个百分点)和未参保患者(高18.8个百分点)相比,参加其他保险的患者总体3年生存率更高。在对分期进行调整后,仍观察到生存率存在重大差异。当考虑II期和III期直肠癌患者时,参加其他保险的患者3年生存率高于参加医疗补助保险的患者(高16.2个百分点)和未参保患者(高12.2个百分点)。然而,当分析仅限于接受放疗后再行根治性手术的II期和III期疾病患者时,医疗补助保险患者和未参保患者的差异分别降至11.8个百分点和7.3个百分点。
对于II期和III期直肠癌患者,未参保患者与参加医疗补助保险以外其他保险的患者在生存率上的差异,很大程度上可由治疗差异来解释。进一步努力确定残余差异的原因,以及努力改善未参保患者获得标准治疗的可及性,可能会提高直肠癌患者群体的生存率。2017年;22:351 - 358对实践的启示:保险状况会影响直肠癌患者的生存率,但如果给予标准治疗,很大一部分生存率差异是可以纠正的。应尽一切努力确保未参保或参加公共保险的患者尽快接受标准治疗,以改善患者预后。